News

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide.

Grenova and its division partners are backed by healthcare-focused private equity firm Peloton Equity.

Hull brings more than 30 years of leadership experience in the life sciences and diagnostics industries and has served on the Grenova Board of Directors for the past 13 months. He previously served as CEO of Bako Diagnostics and Genova Diagnostics – a former FFC company, Peloton’s predecessor firm – and has worked closely with Peloton Equity as an operating partner.

“Given the increasing demand for automation across laboratory workflows, this is a particularly exciting time to build a scaled, integrated platform in this space. Grenova, Peak Robotics, and PAA each bring world-class capabilities in their respective fields, creating a unique set of solutions for our customers,” said Ted Hull. “I’m incredibly excited to work alongside this team to shape the future of scientific automation.”

“We’re thrilled to partner with Ted again,” said Michael O’Rourke, Partner at Peloton Equity. “Ted brings a rare combination of operational leadership, industry expertise, and a deep understanding of how to scale growth companies. Having worked closely with the company and served alongside the leadership team, he is uniquely positioned to lead this next phase of growth.”

With the combined capabilities of Grenova’s technologies and the automation and integration expertise of Peak Robotics and PAA, the organization is positioned to deliver modular, scalable solutions and become a global leader in laboratory automation.

Read more here.

Recent News

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital

05/06/2026

RoVa Labs Opens as Transformational Investment in Roanoke Region’s Innovation Economy

Leaders from Carilion Clinic, the City of Roanoke, Roanoke Blacksburg Innovation Alliance (RBIA), and Virginia Western Community College cut the ribbon on years of hard work with the opening of RoVa Labs, a 40,000-square-foot biotech incubator designed to accelerate commercialization, strengthen the Roanoke Innovation Corridor, and position the region as an emerging destination for life

05/04/2026

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD PPI-Partial Responder Patients at DDW 2026

ISOThrive Inc. announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to proton pump inhibitors (PPIs), demonstrating statistically significant and clinically meaningful reductions in heartburn incidence, severity, and regurgitation. The company’s Chief Medical Officer is presenting these results at Digestive Disease Week (DDW) 2026 this week. NERD represents approximately 70% of